Fernando C Pellegrino1, Roberto E P Sica. 1. Facultad de Ciencias Veterinarias, Universidad de Buenos Aires. Chorroarín 280, Buenos Aires, Argentina. fernandopellegrino@speedy.com.ar
Abstract
OBJECTIVE: The absence of a standardized recording technique and of normal reference patterns may have hindered the use of experimental electroencephalography (EEG) in dogs and in veterinary medicine as well. Therefore, the aim of the present work was to develop a recording technique for brachycephalic, mesocephalic and dolichocephalic breeds of dogs that would standardize the recording parameters, including the electrical activity of the rhinencephalon and prorean gyrus, and to prove its feasibility for detecting abnormal activity. METHODS: We accomplished this task by employing 12 recording electrodes. Three different doses of xylazine (0.5, 1 and 1.5 mg/kg) were used to determine which gave enough sedation to obtain a recording free of artifact. Fifty normal dogs were studied; for comparison 9 epileptic dogs were also explored. RESULTS: We found specific anatomical skull sites where the EEG recording electrodes should be attached; the location of these sites is, in practical terms, the same for every dog, regardless of their skull type. A dose of 1 mg/kg xylazine was chosen for restraining. Normal dogs displayed predominant 6-12 Hz waves which could be recognized all over the cortex. Epileptic dogs were individualized because of the appearance of paroxysmal discharges, composed of spikes, sharp and anomalous sinusoidal waves which usually started in one area, spreading to the whole cortex later on, in the clinical interictal periods. CONCLUSIONS: It was possible to obtain more extensive electrophysiological coverage of the canine cerebral cortex, including the rhinencephalon and prorean gyrus, than previously described in the literature. Intramuscular or subcutaneous xylazine, at a dose of 1 mg/kg, proved to produce the best restraint for recordings. The technique allowed to distinguish abnormal activity in epileptic dogs.
OBJECTIVE: The absence of a standardized recording technique and of normal reference patterns may have hindered the use of experimental electroencephalography (EEG) in dogs and in veterinary medicine as well. Therefore, the aim of the present work was to develop a recording technique for brachycephalic, mesocephalic and dolichocephalic breeds of dogs that would standardize the recording parameters, including the electrical activity of the rhinencephalon and prorean gyrus, and to prove its feasibility for detecting abnormal activity. METHODS: We accomplished this task by employing 12 recording electrodes. Three different doses of xylazine (0.5, 1 and 1.5 mg/kg) were used to determine which gave enough sedation to obtain a recording free of artifact. Fifty normal dogs were studied; for comparison 9 epilepticdogs were also explored. RESULTS: We found specific anatomical skull sites where the EEG recording electrodes should be attached; the location of these sites is, in practical terms, the same for every dog, regardless of their skull type. A dose of 1 mg/kg xylazine was chosen for restraining. Normal dogs displayed predominant 6-12 Hz waves which could be recognized all over the cortex. Epilepticdogs were individualized because of the appearance of paroxysmal discharges, composed of spikes, sharp and anomalous sinusoidal waves which usually started in one area, spreading to the whole cortex later on, in the clinical interictal periods. CONCLUSIONS: It was possible to obtain more extensive electrophysiological coverage of the canine cerebral cortex, including the rhinencephalon and prorean gyrus, than previously described in the literature. Intramuscular or subcutaneous xylazine, at a dose of 1 mg/kg, proved to produce the best restraint for recordings. The technique allowed to distinguish abnormal activity in epilepticdogs.
Authors: Kathryn A Davis; Beverly K Sturges; Charles H Vite; Vanessa Ruedebusch; Gregory Worrell; Andrew B Gardner; Kent Leyde; W Douglas Sheffield; Brian Litt Journal: Epilepsy Res Date: 2011-06-14 Impact factor: 3.045
Authors: Franziska Wielaender; Riika Sarviaho; Fiona James; Marjo K Hytönen; Miguel A Cortez; Gerhard Kluger; Lotta L E Koskinen; Meharji Arumilli; Marion Kornberg; Andrea Bathen-Noethen; Andrea Tipold; Kai Rentmeister; Sofie F M Bhatti; Velia Hülsmeyer; Irene C Boettcher; Carina Tästensen; Thomas Flegel; Elisabeth Dietschi; Tosso Leeb; Kaspar Matiasek; Andrea Fischer; Hannes Lohi Journal: Proc Natl Acad Sci U S A Date: 2017-02-21 Impact factor: 11.205
Authors: Lisa D Coles; Edward E Patterson; W Douglas Sheffield; Jaideep Mavoori; Jason Higgins; Bland Michael; Kent Leyde; James C Cloyd; Brian Litt; Charles Vite; Gregory A Worrell Journal: Epilepsy Res Date: 2013-08-18 Impact factor: 3.045
Authors: Miiamaaria V Kujala; Heini Törnqvist; Sanni Somppi; Laura Hänninen; Christina M Krause; Outi Vainio; Jan Kujala Journal: PLoS One Date: 2013-05-01 Impact factor: 3.240
Authors: Vaclav Kremen; Benjamin H Brinkmann; Inyong Kim; Hari Guragain; Mona Nasseri; Abigail L Magee; Tal Pal Attia; Petr Nejedly; Vladimir Sladky; Nathanial Nelson; Su-Youne Chang; Jeffrey A Herron; Tom Adamski; Steven Baldassano; Jan Cimbalnik; Vince Vasoli; Elizabeth Fehrmann; Tom Chouinard; Edward E Patterson; Brian Litt; Matt Stead; Jamie Van Gompel; Beverly K Sturges; Hang Joon Jo; Chelsea M Crowe; Timothy Denison; Gregory A Worrell Journal: IEEE J Transl Eng Health Med Date: 2018-09-26
Authors: Ritobrato Datta; Jongho Lee; Jeffrey Duda; Brian B Avants; Charles H Vite; Ben Tseng; James C Gee; Gustavo D Aguirre; Geoffrey K Aguirre Journal: PLoS One Date: 2012-12-20 Impact factor: 3.240